BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
Stock Information for BioLineRx Ltd.
Loading
Please wait while we load your information from QuoteMedia.